MONDAY 9 JUNE | Wembley Stadium

TIME	SESSION/LOCATION			
08:00 – 09:00	Registration (Pre-Conference session: Introduction for students and new starters – Lizzi Pitt, Jemma Greenin and Oswald Dellimore)			
	Great Hall			
09:00 – 09:30	**Conference Opening Remarks** *Sarah Williams, PSI Conference Chair*			
09:30 – 10:30	**Communicating the magic of maths (PL1)** *Alex Bellos is one of the UK's most celebrated maths communicators. He has sold more than a million books, writes a popular puzzle column in the Guardian and appears regularly on Radio 4. In this talk he will explain what he has learned about communicating maths to different audiences. You will hear stories, see beautiful images and solve some puzzles!* *Chair: Sarah Williams* *Alex Bellos*			
10:30 – 11:00	Refreshment Break in Bobby Moore Room			
	Great Hall	Wembley Suite	Pitch View East	The Arc
11:00 – 12:30	**The Fearless Statistician: Psychological Safety in Drug Development (O002)** *Chair: Lucy Rowell* *Introduction to psychological safety and its relevance to statisticians working in the pharmaceutical Industry - Dirk Klingbiel* *Organizational Approaches to Psychological Safety: Building Inclusive and High-Performing Statistical Teams - Clélia Cahuzac* *Quantifying the costs of a lack of psychological safety - A case series - Anna Wiksten*	**AI/ML SIG: updates and applications (O003)** *Chair: Sam Hadlington* *Predicting with uncertainty - Chris Harbron* *AI Generated Synthetic Control Arms to optimize Clinical Trials- Paola Berchialla and Danila Azzolina* *Explainable AI for Causal Inference and Heterogeneous Treatment Effect Estimation via AI/ML – a conceptual framework for late phase clinical trials - Karl Koechert and Eliana Garcia-Cossio* *Panel Discussion: Sam Hadlington, Chris Harbron, Paola Berchialla,*	**Borrowing Strength or Buying Trouble? Using External Data in Regulatory Context (O006)** *Thinking beyond the norm: how to (fairly) evaluate Bayesian Dynamic Borrowing Designs - Gaëlle Saint-Hilary* *Another form of hybrid trial designs with external information: extrapolation in Paediatrics - Juan Jose Abellan* *Echo of the Past: The Pre-specification Challenge in Hybrid RCTs - Franz König* *Challenges when using external control data for regulatory decision making - Florian Klinglmueller*	**PFDD SIG: How to use PROs in early development (O011)** *Chair: Konstantina Skaltsa* *Devin Peipert* *Alexandra Lauer* *Evgeniya Reshetnyak* *Hot topics: Rachael Lawrance*

	Panel discussion: Justine Rocheon, Dirk Klingbiel, Clélia Cahuzac and Anna Wiksten	*Danila Azzolina, Karl Koechert and Eliana Garcia-Cossio*		
12:30 – 13:30	Lunch in Bobby Moore Room (Career Young Networking Session – Lizzi Pitt, Jemma Greenin and Oswald Dellimore) (Book Club Networking Session – Emma May)			
	Great Hall	Wembley Suite	Pitch View East	The Arc
13:30 – 15:00	**Navigating the Move to Open Source - Effective Strategies for Adoption and Working with Different Software (O010)** *R Adoption & Change Management – a Large CRO Perspective - Martin Brown* *Mastering the Art of Adopting R and Python: Innovative Strategies for Effective Change Management - Mark Bynens* *R you (all) right, SAS? – Replicating statistical results between software - Lyn Taylor and Christina Fillmore*	**Grow your own way (W2)** *Isabelle Smith* *Lucy Rowell*	**SEE-ing the Future: Empowering Health Decisions through Structured Expert Elicitation (O008)** *Chair: Min-Hua Jen* *Roel Straetemans* *Kate Ren* *Christopher Jackson* *Hugo Pedder* *Followed by Q&A*	**CYS** *Powering RCTs for marginal effects with GLMs using prognostic score adjustment (CYS01) - Emilie Hojbjerre-Frandsen* *Is there really any benefit to stratified randomisation in practice? (CYS05) - Pavankumar Bhagat* *Frailty prediction using digital sensor data, an interpretable machine learning approach (CYS06) - Gaizka Pérez* *Reconstructing Individual Patient Level Survival Data from Aggregate Survival Data using a Simulation Approach (CYS07) - Sarwar Mozumder* *Development and Evaluation of a Predictive Ensemble Learning Framework for Breast Cancer Radiotoxicities at 2 Years (CYS08) Samana Bano and Rebecca Boucher*
15:00 – 15:30	Changeover			
	Great Hall	Wembley Suite	Pitch View East	The Arc
15:30 – 16:45	**Causal Inference in clinical trails** *DoubleMLDeep: Estimation of Causal Effects with Multimodal Data (O023) - Martin Spindler*	**Bayesian/Master Protocols** *Bayesian life-course modelling of Alzheimer's Disease progression (O033) - David Lunn*	**Dose Optimisation** *Chair: Ayon Mukherjee*	**CYS 2** *Applying prognostic scoring adjustments to enhance clinical trial*

	Decoding optimal methods in treatment switching: Recommendations from oncology-inspired simulation studies (O027) - Orlando Doehring *Targeted Maximum Likelihood Estimation for Restricted Mean Survival Time in time-to-event data with low event rates: a case study using a previous non-randomised PAS study (O045) - Michael Seath* *Vaccine Efficacy waning estimation and extrapolation using causal inference (O047) - Jyoti Soni and Andrea Callegaro*	*A basket trial design based on constrained hierarchical Bayesian model for latent subgroups (O036) - Atsuki Hashimoto* *Optimizing Paediatric Outcomes: Advanced Bayesian Modelling of Days Without Mechanical Ventilation in Respiratory Trials (O043) - Danila Azzolina*	*Designing a seamless P1/P2a open enrolment CRM dose escalation study (O025) - Elias Laurin Meyer* *Evaluating Early-Stage Oncology Clinical Trials in the Era of Project Optimus: A scoping review (O029) - Anais Andrillon* *A review of innovative seamless phase I/II design in early drug development in Oncology (O030) - Laurence Collette* *The Optimus Journey: FDA-Approved Examples of Dose Optimization in FIH Oncology Trials (O046) - Benoit Sansas*	*efficiency in neurodegenerative diseases (CYS02) - Harry Parr* *Three new methodologies for calculating the effective sample size when performing population adjustment (CYS03) - Landan Zhang* *Context-dependent response-adaptive randomization for continuous endpoints and applications (CYS04) - Luca Rondano* *When to schedule the interim analysis in the presence of missing data? (CYS09) - Neža Dvoršak*
16:45 – 17:00	Refreshment Break in Bobby Moore Room			
	Great Hall			
17:00 – 17:45	**Gone in 45 seconds** *Chairs: Kate Taylor and Tom Burnett*			
	Bobby Moore Room			
17:45 – 18:45	**Poster Session**			
19:30 – 22:00	Monday Night Social at BOXPARK, Wembley *Sponsored by Alira Health*			

MONDAY 9 JUNE | POSTER SESSION | 17:45 – 18:45

Poster ID	Title	Presenting Author
P001	Using a Poisson Mixed-Effects Model to Improve Detection of Underreporting and Overreporting of Adverse Events in Multicentre Clinical Trials	Lawson Wang
P002	Adaptive design of clinical trials with delayed treatment effects using elicited prior distributions	James Salsbury
P003	Optimising graph-based multiple testing procedures by incorporating clinical considerations into flexible power objectives for FWER control	Alex Spiers
P004	Enhancing Clustering Quality Through the Integration of Missing Data Patterns: A Hierarchical Approach	Berit Hunsdieck
P005	Empirical aspects of MCPMod for Time to Event with Bayesian Borrowing	Erik Hermansson
P006	Project Optimus: A generalised Bayesian analytical framework for multi-endpoint dose optimisation	Miguel Pereira
P007	A basket trial design for dose optimization using Bayesian model averaging	Belay Birlie Yimer
P008	SISAQOL-IMI Recommendations: Statistical Considerations for Advancing PRO Analysis for Cancer Clinical Trials	Michael Schlichting
P009	An Alternative Estimand for Overall Survival in the Presence of Treatment Discontinuation: Simulation Results and Case Study	Kara-Louise Royle
P010	Assessing the Effects of Additional Investment in Earlier Phase Trials to Enhance Overall Program Probability of Success Through Informed Priors	Valeria Mazzanti
P011	PolyMAIC: Retain more of your hard-earnt clinical trial information	Jason Wilson
P012	A modelling strategy for the dose-escalation Phase I trials with a large number of combination-schedules	Weishi Chen
P013	On the use of the intraclass correlation coefficient for validation of count data endpoints in clinical trials	Antonio Rodríguez
P014	Targeted Maximum Likelihood Estimation for covariate adjustment in a Phase 3 randomized controlled study	Michael Seath
P015	Optimizing Clinical trials	Tom Parke
P016	Integrating Synthetic Data and AI in Paediatric Intensive Care Clinical Trials: A Bayesian Framework for Ethical and Scientific Advancement	Danila Azzolina
P017	Collaborative initiative for joint modelling of clinical, biomarker, and pharmacometrics data for dose and schedule optimization in an oncology phase-1 clinical trial	Federico Rotolo
P018	Enhancing Ulcerative Colitis Clinical Trials: A Cost-Efficient Umbrella (Proof-of-Concept) Study Design Leveraging Historical Data	Alexia Kakourou
P019	From Classroom to Clinical Trials: How PSI is inspiring the next generation of statisticians	Katie Law

P020	Navigating Non-Randomized Data in Health Technology Assessments in light of the EU HTA - complexities and solutions	Mona Bierl
P021	Multivariate signature modelling of itch outcomes in primary biliary cholangitis	Jasna Cotic
P022	Diversifying Clinical Trials with Adaptive Targeted Maximum Likelihood Estimation (A-TMLE): A Data Fusion Approach for Real-World Evidence	Rachael Phillips
P023	Sample Size Re-estimation: Exploding the Myths	Christopher Jennison
P024	Streamlining clinical trial data visualisation and reporting: a Python and R hybrid solution	Miguel Pereira
P025	Ordering Treatments Under Uncertainty	Justin Chumbley
P026	Population Adjustment for Indirect Comparisons: Making Apples and Oranges Play Nice	Sarah Robson
P027	Improving Model Accuracy for Skewed Data: A Depression Trial Example	Mohd Rashid Khan
P028	Hurricanes, Elections and Clinical Trials: Some novel approaches to visualising uncertainty.	Steve Mallett
P029	Adaptive group sequential designs with constraints on the information fraction	Fredrik Öhrn
P030	The Underlap Coefficient: A Novel Alternative to ROC-Based Summary Measures for Evaluating Biomarkers' Discriminatory Ability in Multi-Class Settings	Zhaoxi Zhang
P031	Introducing {verifyr2}: An R package for accelerating clinical study output review process	Anna Wiksten
P032	Potential applications of the principal stratum strategy in PRO endpoints	Konstantina Skaltsa
P033	Mind the EGAP: Using the Evidence Generation Analysis Plan to coordinate analyses that are outside the scope of existing analysis plans	Katy White
P034	ePRO for primary endpoints?	Barbara Arch
P035	Exploring PSI's Introduction to Industry Training (ITIT) Course: Benefits for Participants and Hosts	Sam Ruddell
P036	Conducting Efficient Clinical Trials in Immuno-oncology: Insights from Seven Years of the Morpheus Platform Trial	Clelia Cahuzac
P037	Enhancing Precision in Subgroup Analyses Using Bayesian Shrinkage Estimation: A Case Study	Dawn Edwards
P038	Evaluating External Control Feasibility for an Investigational Therapy in a Neuromuscular Disorder: A Simulation Study	Robbie Peck
P039	Investigating Causal Effects in Survival Analysis: How Adjustment Methods Shape Treatment Estimates	Frederikke Agerbo Modin
P040	Proof of target engagement in phase 1 trials with MCP-Mod	Valeria Bonapersona
P041	Machine Learning in Precision Medicine: A Collaborative Approach	Laura Schlieker

P042	Championing Diversity and Inclusion: PSI's New DE&I Working Group	Justyna Mlynarczyk
P043	Survival odds in risk heterogeneous populations	Robin Myte
P044	Apprentice Statistician: Maximising our potential significance	Sarah Crossley
P045	Sample size calculation for estimands with time-to-event variables	Daniel Bratton
P046	The Curious Case of External Controlled Arms (ECA): Application to a Randomized Controlled Trial in Alzheimer’s Disease	Flaminia Chiesa
P047	Optimal utility-based design of phase II/phase III programmes with different type of endpoints in the setting of multiple myeloma	Haotian Wang
P048	Standardising Sensitivity Analysis in Clinical Trials - A Tipping Point Approach	Nicolas Dubois
P049	Open-source modular approach to Safety Visualization, Monitoring, Review and Analysis	Matthias Trampisch
P050	Litmusverse: An Open-Source Suite for Comprehensive Assessment of R Package Quality	Pedro Silva
P051	(Almost) One Million Ways to Define Change – Analysing PROs in the EU-HTA Context	Jens Oldeland
P053	A Bayesian precision-medicine decision framework for pursuing biologically plausible predictive biomarkers in early clinical development — a pivot towards risk-benefit analysis when false negatives matter as much as false positives	Mathias Cardner
P054	Calculating conditional power under non-proportional hazards	Michael Grayling
P055	Exact Matching as an Alternative to Propensity Score Matching	Ekkehard Glimm
P056	Two-Missed Visit Censoring Rule in Oncology Trials: Robust Strategy or Bias Amplifier?	Michael Sweeting
P057	“Measurement Error-Free” Analysis of Clinical Trial Data using Structural Equation Modelling	Piper Fromy
P058	Semantic similarity-based Bayesian borrowing for quantitative safety signal detection in spontaneous reporting systems	François Haguinet
P059	Leveraging real-world evidence and data pooling for a comprehensive analysis of the patient journey in a rare disease	Fern Hughes
P060	Allocation Ratios Achieving Maximal Power in Controlled Experiments: Implications for Randomization in Two-Arm, Umbrella and Platform Trials	Peter Jacko